The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
milestone payment in August?
INDV-1000 (Selective Orexin 1 [OX1] receptor antagonist):
- On September 26, 2019 the National Institutes of Health (NIH) granted Indivior’s application
entitled “Clinical Evaluation of C4X3256, a Non-Opioid, Highly-Selective Orexin-1 Receptor Antagonist for
the Treatment of Opioid Use Disorder” pursuant to Funding Opportunity Announcement RFA-DA-19-002
dedicated to the development of medications to prevent and treat opioid use disorder and overdose.
Page | 2
- Our development plans were presented at the first HEAL Investigator Meeting in Bethesda on January 16-
17, 2020 (see publication list).
- The Single Ascending Dose (SAD) study was planned to start in April 2020 but was delayed by
approximately 3 months due to the COVID-19 pandemic. The first dosing in Man is currently scheduled for
August 2020.
- Nonclinical pivotal toxicokinetics and embryofetal studies have been completed.
maybe, but what is the point of communicating something if it is not meaningful.
The point here is the INDV deal looked in serious doubt (I think around 20-25M was gradually wiped off the SP) and now it looks back on track. The initial 15p fund raise was another kick in the nuts but hopefully the worst is now over.
The share is so illiquid that if you get caught out on the wrong side of the trade it can be very painful short term.
Notmyjob.
every small company posts that kind of mush it is just par for the course.
The key here is the big Indivior deal looks back on track as the company (INDV) has resolved there legal battle which looked like it might have sunk them 12 months ago.
Around the time of the deal the SP was well over 100p and now things have moved on as a compound is now in the clinic.
Even allowing for the dilution this should be getting back to around 80p not only for the potential milestone payments from this deal and other deals that should be close, but for potential as a takeover target.
Yeah but they are going to get 3-5 million quid for the asset sale...oh wait..
This isn't a viable company anymore. It is just a mechanism for the brokers/lawyers and directors to rinse the last few quid out before the curtain comes down on MWG.
AI today is what .com was in the late 90's. Investors chucking their money at it as it suggests faster and cheaper ways of doing things.
With regards to drug discovery, sure it will be a helpful tool in the process but I doubt it will be the holy grail that is suggested by the folks raising money....imo of course
Good news on getting some deals. Would be nice to know how much cash they got on up front on signing these deals as that is what matters
or Suhail and co. are playing you for fools and trading in and out of the spikes while everyone else averages down
Nah
It'll be a SunUp StitchUp.
Announced just as the market closes on Xmas Eve
depends as ever on the price they get.
My opinion now is Sunup is going to pick this up on the cheap but rather than wait for it to go bust and the potential hassle of getting the parts they want, offer around 1p for the shares, hence why the price hasn't completely collapsed.
there's no money left